Invest in Ventoux Biosciences

Transforming Dupuytren's Disease Treatment Novel Non-Surgical Disease Slowing Treatments

Exclusive
Friends Invest First
Public Launch on Jun 10 @ 8:00 PM ET
34
day
12
hour
59
min
23
sec
INVESTMENT TERMS
Future Equity
$12M valuation cap

Highlights

1
Dupuytren's impacts >40m patients in US and Europe and global disease market size est. at USD $4.3B
2
No cure and no approved pharmacologic disease modifying options, surgery is mainstay of treatment
3
High patient dissatisfaction with limited treatment options, strong interest in novel options
4
VEN-201, our lead asset, represents a potential paradigm shift in treatment

Our Team

Founder, CEO
>25 years of biotechnology and pharmaceutical operational and commercial leadership, early stage product development, launch, and in-market optimization Expertise in specialty markets including immunology, pain/ inflammation, fibrosis, and surgery.
Chief Scientific Officer, VP Corporate Strategy
Highly accomplished research leader in fibrosis and cancer target validation, drug discovery, and translational research. Dr. Lipson's work is represented in over 100 publications in peer-reviewed journals, review articles, book chapters, and patent app
Laxma ReddyVP, Product Development
Dr. Laxma Reddy is the Vice President of Product Development for Ventoux Biosciences. Dr. Reddy is a biochemist, protein chemist, and pharmaceutical development scientist with >30 years of experience in drug discovery, preclinical development, and sustain

Transforming the $4B Dupuytren's Disease Market with Novel Non-Surgical Treatments




























Downloads

Overview